ClinicalTrials.gg
CompletedNCT00962091Updated Mar 12, 2019Results posted

Study of MLN8237 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Alisertib in Advanced Solid Tumors, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-12.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC) formulation, to characterize the effect of food on the single-dose pharmacokinetics (PK) of alisertib OS and enteric-coated tablets (ECT), to characterize the multiple-dose safety, tolerability, and steady-state PK of alisertib administered as an OS, and to characterize the multiple-dose safety and tolerability of alisertib administered as an ECT.

Read the detailed description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have advanced solid tumors. This study will look at the relative bioavailability (BA) (Part A), food effect and multiple-dose PK and safety of the oral solution (OS) (Part B) and food effect and safety of the enteric-coated tablet (ECT) formulation (Part C).

The study enrolled 53 patients (pts). Prior to initiation of Part A, 4 participants were enrolled in a dose escalation cohort. Participants in the study received:

  • Alisertib 15 mg to 50 mg orally In the first 2 cycles of all 3 parts of the study, a single dose of alisertib was administered on Day 1 (PIC or OS in Part A [n=19 pts]; OS, in the fed or fasted state, in Part B [n=6 pts]; ECT, in the fed or fasted state, in Part C [n=24 pts]), In Part A, participants then continued on the PIC formulation at 40 mg BID for 7 days (Days 3 - 9). In Part B, participants continued on the OS formulation at a calculated dose administered BID for 7 days (Days 3 - 9). In Part C, the ECT formulation was continued at 40 mg BID for 7 days (Days 3 - 9); however, dose escalation to 50 mg BID was permitted after Cycle 1 based on tolerability and safety findings in the prior cycles. All participants took doses at a gap of 12 hours each day for 7 days followed by a 14-day rest period in a 21-days cycle for the remaining cycles.

This multi-center trial was conducted in the United States. The overall time to participate in this study was 30 months. Participants made multiple visits to the clinic, and final assessments were performed approximately 30 days after last dose of study drug.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Drug therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

  • 18 years or older
  • or cytologically confirmed and/or advanced solid tumor
  • (ECOG) performance status 0 or 1
  • Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of or abstain from heterosexual intercourse
  • Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse
  • Voluntary written consent
  • Suitable venous access for study-required blood sampling
  • Recovered from effects of prior antineoplastic therapy
  • Meet required entry laboratory and organ function levels

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Female participants who are pregnant or lactating
  • Serious medical or psychiatric illness that could interfere with protocol completion
  • Major surgery within 14 days of first dose of alisertib
  • Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of alisertib
  • Nitrosoureas or mitomycin-C within 6 weeks before the first dose of alisertib.
  • stem cell transplant within 3 months before the first dose of alisertib, or prior allogeneic stem cell transplant at any time.
  • Active infection requiring systemic therapy, or other serious infection
  • Inability to swallow oral medication
  • Gastrointestinal (GI) disease or GI procedure that could interfere with oral absorption or tolerance of alisertib
  • Symptomatic
  • Uncontrolled cardiovascular condition
  • Diagnosis or treatment of another within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
  • Known history of (HIV) infection, , or
  • Lactose-intolerant (Parts A and B only)
  • Prior history of metabolic acidosis (Parts A and B only)
  • Use of enzyme-inducing antiepileptic drugs such as phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of alisertib
  • A medical condition requiring use of pancreatic enzymes; or daily, chronic , or regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists. Participants who intermittently use these medications must meet the following:

    • No use of PPI within 7 days of first dose of alisertib
    • No use of H2 antagonist or pancreatic enzymes within 24 hours of first dose of alisertib
  • Participants requiring full systemic anticoagulation
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    A single dose of alisertib 15 mg, oral solution (OS) was administered on Day 1, followed by alisertib 40 mg, powder-in-capsule (PIC), orally, twice a day (BID) on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, was administered on Cycle 2 Day 1 followed by alisertib 40 mg on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Subsequent cycles, alisertib 40 or 50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.

    Drug: Alisertib

  • Experimental
    Part A: Relative Bioavailability OS/PIC (Sequence A)

    A single dose of alisertib 25 mg, OS, administered on Day 1, followed by alisertib 40 mg PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, administered on Cycle 2 Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles, alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.

    Drug: Alisertib

  • Experimental
    Part A: Relative Bioavailability PIC/OS (Sequence B)

    A single dose of alisertib 50 mg, PIC, orally administered on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 25 mg, OS, once on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles followed by alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in Cycle 3, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.

    Drug: Alisertib

  • Experimental
    Part B: OS Food Effect Fed/Fasted (Sequence A)

    Alisertib 35 mg (35 mg = relative bioavailability estimate in Part A as dose of OS that was calculated to yield the area under the concentration time curve of a 50-mg PIC dose): A single dose of alisertib 35 mg oral solution (OS), in fed state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 35 mg administered, OS, in fasted state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg, PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted, based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.

    Drug: Alisertib

  • Experimental
    Part B: OS Food Effect Fasted/Fed (Sequence B)

    A single dose of alisertib 35 mg, OS, in fasted state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 2 Day 1 alisertib 30 mg, OS administered in fed state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.

    Drug: Alisertib

  • Experimental
    Part C: ECT Food Effect Fed/Fasted (Sequence A)

    Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 40 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Cycle 3 onwards, participants were administered alisertib 40 mg BID ECT on Days 1-7 with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.

    Drug: Alisertib

  • Experimental
    Part C: ECT Food Effect Fasted/Fed (Sequence B)

    Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 mg, ECT, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2, a 23-day cycle. Cycle 3 onwards participants were administered alisertib 40 mg BID ECT on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.

    Drug: Alisertib

Interventions

  • Alisertib OS Alisertib PIC Alisertib PIC

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)

    Dose normalized Cmax was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.

    Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual adverse event (AE) that was judged by the investigator to be treatment related.

  2. Part A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)

    Dose normalized AUClast was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.

    Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  3. Part B: Cmax: Maximum Observed Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food

    Not performed.

    Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  4. Part B: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food

    Not performed.

    Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  5. Part B: Cmax: Maximum Plasma Concentration for Alisertib Oral Solution Following Multiple-Dose Administration

    Not performed.

    Time frame: Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  6. Part B: Tmax: Time of First Occurrence of Cmax Over the Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration

    Not performed.

    Time frame: Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  7. Part B: AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration

    Not performed.

    Time frame: Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  8. Part C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food

    Participants were randomized to receive 50-mg alisertib as an ECT (single, 50-mg strength tablets) under fasted or fed (following a standardized high-fat meal) conditions.

    Time frame: Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  9. Part C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food

    Time frame: Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  10. Part C: AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food

    Time frame: Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

  11. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: Up to 30 days after the last dose of study drug (up to 27.4 months)

  12. Number of Participants With Abnormal Laboratory Values Reported as Adverse Events at an Incidence of at Least 5%

    Laboratory AEs reported at an incidence of at least 5% overall in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, metabolism and nutrition disorders, investigations, and hepatobiliary disorders. Abnormal laboratory value were assessed as an AE if the value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Up to 30 days after the last dose of study drug (up to 27.4 months)

  13. Number of Participants With Abnormal Vital Signs Reported as Adverse Events

    Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study.

    Time frame: Up to 30 days after the last dose of study drug (up to 24 months approximately)

Secondary outcomes

  1. Best Overall Response (CR+PR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Best overall response is defined as the number of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum LD since the treatment started.

    Time frame: At the completion of Cycle 2 and every 2 cycles (every 6 weeks) until Cycle 6 (18 weeks). After Cycle 6 (18 weeks), CT/MRI scans (with contrast) were to be performed every 3 cycles (9 weeks) until PD was documented.

07

Results

Posted Mar 12, 2019

Participant flow

Participants took part in the study at 3 investigative sites in the United States from 25 September 2009 to 01 July 2014.

Participant flow — Overall Study
MilestoneDose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)
Started4910331212
Completed379231111
Not completed1211011
Withdrew: Withdrawal by subject1211010
Withdrew: Adverse event0000001

Outcome measures

PrimaryPart A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)

Dose normalized Cmax was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.

Time frame:
Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual adverse event (AE) that was judged by the investigator to be treatment related.
Reported as:
Mean · nM/mg
Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)
nM/mgPart A: Alisertib OSPart A: Alisertib PIC
Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)58.78 ± 22.58331.40 ± 11.404
Statistical analysis
  • Part A: Alisertib OS vs Part A: Alisertib PIC · Geometric mean ratio: 1.90 · 90% CI 1.52 to 2.37The CIs are calculated for the difference in the LS means of the ln-transformed Day 1 Cmax values (difference=OS-PIC). Antilogs of the confidence limits for the difference are taken to construct the CIs for the ratio of the geometric means.
PrimaryPart A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)

Dose normalized AUClast was obtained using Cmax divided by alisertib dose in milligrams to provide values adjusted to a 1 mg alisertib dose.

Time frame:
Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Reported as:
Mean · nM*hr/mg
Part A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)
nM*hr/mgPart A: Alisertib OSPart A: Alisertib PIC
Part A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)530.18 ± 177.750372.53 ± 145.190
Statistical analysis
  • Part A: Alisertib OS vs Part A: Alisertib PIC · Geometric mean ratio: 1.38 · 90% CI 1.08 to 1.78The CIs are calculated for the difference in the LS means of the ln-transformed Day 1 AUClast values (difference=OS-PIC). Antilogs of the confidence limits for the difference are taken to construct the CIs for the ratio of the geometric means.
PrimaryPart B: Cmax: Maximum Observed Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food

Not performed.

Time frame:
Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

No measurements were reported for this outcome.

PrimaryPart B: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food

Not performed.

Time frame:
Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

No measurements were reported for this outcome.

PrimaryPart B: Cmax: Maximum Plasma Concentration for Alisertib Oral Solution Following Multiple-Dose Administration

Not performed.

Time frame:
Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

No measurements were reported for this outcome.

PrimaryPart B: Tmax: Time of First Occurrence of Cmax Over the Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration

Not performed.

Time frame:
Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

No measurements were reported for this outcome.

PrimaryPart B: AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration

Not performed.

Time frame:
Cycle 1 Day 9 predose and at multiple time points (up to 12 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.

No measurements were reported for this outcome.

PrimaryPart C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food

Participants were randomized to receive 50-mg alisertib as an ECT (single, 50-mg strength tablets) under fasted or fed (following a standardized high-fat meal) conditions.

Time frame:
Cycles 1 and 2 Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Reported as:
Mean · nM
Part C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
nMPart C: Alisertib ECT (Fasted State)Part C: Alisertib ECT (Fed State)
Part C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food1757.9 ± 924.51401.2 ± 501.0
Statistical analysis
  • Part C: Alisertib ECT (Fasted State) vs Part C: Alisertib ECT (Fed State) · Geometric mean ratio: 0.84 · 90% CI 0.66 to 1.06The CIs are calculated for the difference in the LS means of the ln-transformed Day 1 Cmax values (difference=Fed-Fasted). Antilogs of the confidence limits for the difference are taken to construct the CIs for the ratio of the geometric means.
PrimaryPart C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
Time frame:
Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Reported as:
Mean · nM*h
Part C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
nM*hPart C: Alisertib ECT (Fasted State)Part C: Alisertib ECT (Fed State)
Part C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food23928.6 ± 14343.5624135.0 ± 11757.15
Statistical analysis
  • Part C: Alisertib ECT (Fasted State) vs Part C: Alisertib ECT (Fed State) · Geometric mean ratio: 1.04 · 90% CI 0.80 to 1.34The CIs are calculated for the difference in the LS means of the ln-transformed Day 1 AUClast values (difference=Fed-Fasted). Antilogs of the confidence limits for the difference are taken to construct the CIs for the ratio of the geometric means.
PrimaryPart C: AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
Time frame:
Cycles 1 and 2 on Day 1 predose and at multiple time points (up to 48 hours) postdose, and, if clinically feasible, at the time of a serious or unusual AE that was judged by the investigator to be treatment related.
Reported as:
Mean · nM*h
Part C: AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food
nM*hPart C: Alisertib ECT (Fasted State)Part C: Alisertib ECT (Fed State)
Part C: AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food30627.3 ± 21000.2928507.1 ± 15637.50
Statistical analysis
  • Part C: Alisertib ECT (Fasted State) vs Part C: Alisertib ECT (Fed State) · Geometric mean ratio: 0.94 · 90% CI 0.68 to 1.32The CIs are calculated for the difference in the LS means of the ln-transformed Day 1 AUC values (difference=Fed-Fasted). Antilogs of the confidence limits for the difference are taken to construct the CIs for the ratio of the geometric means.
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
Up to 30 days after the last dose of study drug (up to 27.4 months)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsDose Escalation CohortPart A: Relative BioavailabilityPart B: OS Food EffectPart C: ECT Food Effect
AE419624
SAE24211
PrimaryNumber of Participants With Abnormal Laboratory Values Reported as Adverse Events at an Incidence of at Least 5%

Laboratory AEs reported at an incidence of at least 5% overall in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, metabolism and nutrition disorders, investigations, and hepatobiliary disorders. Abnormal laboratory value were assessed as an AE if the value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Up to 30 days after the last dose of study drug (up to 27.4 months)
Reported as:
Number · participants
Number of Participants With Abnormal Laboratory Values Reported as Adverse Events at an Incidence of at Least 5%
participantsDose Escalation CohortPart A: Relative BioavailabilityPart B: OS Food EffectPart C: ECT Food Effect
Neutropenia38221
Leukopenia37217
Anaemia34215
Thrombocytopenia43310
Lymphopenia0303
Hypomagnesaemia0017
Hyperglycaemia0113
Hypokalaemia0013
White blood cell count decreased0015
Aspartate aminotransferase increased1006
Gamma-glutamyltransferase increased0102
Lymphocyte count decreased0003
Neutrophil count decreased0102
Hyperbilirubinaemia1003
PrimaryNumber of Participants With Abnormal Vital Signs Reported as Adverse Events

Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study.

Time frame:
Up to 30 days after the last dose of study drug (up to 24 months approximately)
Reported as:
Number · participants
Number of Participants With Abnormal Vital Signs Reported as Adverse Events
participantsDose Escalation CohortPart A: Relative BioavailabilityPart B: OS Food EffectPart C: ECT Food Effect
Hypertension1011
Hypotension0110
Tachycardia1110
Sinus bradycardia0001
SecondaryBest Overall Response (CR+PR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Best overall response is defined as the number of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum LD since the treatment started.

Time frame:
At the completion of Cycle 2 and every 2 cycles (every 6 weeks) until Cycle 6 (18 weeks). After Cycle 6 (18 weeks), CT/MRI scans (with contrast) were to be performed every 3 cycles (9 weeks) until PD was documented.
Reported as:
Number · participants
Best Overall Response (CR+PR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
participantsDose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)
Best Overall Response of CR or PR0000000
Best Overall Response of Stable Disease0152166

Adverse events

Collected over Up to 30 days after the last dose of study drug (up to 27.4 months approximately). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation Cohort—2/4 (50%)4/4 (100%)
Part A: Relative Bioavailability—4/19 (21.1%)19/19 (100%)
Part B: OS Food Effect—2/6 (33.3%)6/6 (100%)
Part C: ECT Food Effect—11/24 (45.8%)24/24 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventDose Escalation CohortPart A: Relative BioavailabilityPart B: OS Food EffectPart C: ECT Food Effect
NeutropeniaBlood and lymphatic system disorders1/40/190/61/24
HyperbilirubinaemiaHepatobiliary disorders1/40/190/60/24
DehydrationMetabolism and nutrition disorders1/41/190/60/24
Febrile neutropeniaBlood and lymphatic system disorders0/41/191/62/24
FatigueGeneral disorders0/40/191/60/24
PainGeneral disorders0/40/191/60/24
SepsisInfections and infestations0/40/191/60/24
VomitingGastrointestinal disorders0/41/190/61/24
HydronephrosisRenal and urinary disorders0/41/190/61/24
NauseaGastrointestinal disorders0/41/190/60/24
Most frequent other events
Showing 10 of 131
Most frequent other events
EventDose Escalation CohortPart A: Relative BioavailabilityPart B: OS Food EffectPart C: ECT Food Effect
StomatitisGastrointestinal disorders4/47/195/66/24
ThrombocytopeniaBlood and lymphatic system disorders4/43/193/67/24
LeukopeniaBlood and lymphatic system disorders3/47/192/613/24
AnaemiaBlood and lymphatic system disorders3/44/192/613/24
FatigueGeneral disorders3/412/194/611/24
NeutropeniaBlood and lymphatic system disorders2/48/192/617/24
DiarrhoeaGastrointestinal disorders0/411/191/613/24
AlopeciaSkin and subcutaneous tissue disorders1/45/191/613/24
NauseaGastrointestinal disorders2/410/192/69/24
PyrexiaGeneral disorders2/42/192/61/24

Baseline characteristics

Safety population is defined as all participants who receive any amount of alisertib. Efficacy analysis included all participants who had a baseline response assessment and at least one on-study response assessment.

Age, Continuous
Age, Continuous(years)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
Mean58.3 (57 to 59)54.6 (20 to 71)54.0 (36 to 70)51.7 (31 to 64)57.7 (53 to 61)57.4 (39 to 72)55.2 (46 to 69)55.5 (20 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
Female325117928
Male175225325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
Hispanic or Latino00201216
Not Hispanic or Latino49832101147
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
White48932121149
Black or African American00101013
Asian01000001
Region of Enrollment
Region of Enrollment(participants)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
United States491033121253
Height
Height(cm)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
Mean167.7 (163 to 175)172.6 (154 to 185)172.8 (160 to 188)160.3 (157 to 163)169.1 (159 to 182)169.2 (159 to 179)160.5 (152 to 169)167.4 (152 to 188)
Weight
Weight(kg)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
Mean72.7 (66 to 80)85.5 (68 to 118)81.4 (65 to 120)66.3 (45 to 99)77.7 (59 to 99)73.0 (45 to 98)66.1 (43 to 101)74.7 (43 to 120)
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Dose Escalation CohortPart A: Relative Bioavailability OS/PIC (Sequence A)Part A: Relative Bioavailability PIC/OS (Sequence B)Part B: OS Food Effect Fed/Fasted (Sequence A)Part B: OS Food Effect Fasted/Fed (Sequence B)Part C: ECT Food Effect Fed/Fasted (Sequence A)Part C: ECT Food Effect Fasted/Fed (Sequence B)Total
Mean1.84 (1.7 to 2.0)2.02 (1.8 to 2.4)1.97 (1.7 to 2.5)1.69 (1.4 to 2.1)1.90 (1.6 to 2.2)1.82 (1.4 to 2.2)1.68 (1.4 to 2.1)1.85 (1.4 to 2.5)
08

Study locations

1 site
  • Premiere Oncology, A Medical Corporation
    Santa Monica, California 90404, United States
09

References and documents

Publications

  • Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs R D. 2016 Mar;16(1):45-52. doi: 10.1007/s40268-015-0114-8. PubMed 26689566 ↗
  • Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2015 Jul;53(7):563-72. doi: 10.5414/CP202359. PubMed 26073352 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2009 to primary completion in Dec 2011, 27 months.

Results were first posted in Mar 2019, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2009
First posted
Aug 19, 2009
StartActual
Sep 25, 2009
Primary completionActual
Dec 28, 2011
CompletionActual
Jul 1, 2014
Results first posted
Mar 12, 2019
Last update
Mar 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00962091
Responsible party
Sponsor
First posted
Aug 19, 2009
Start date
Sep 25, 2009
Primary completion
Dec 28, 2011
Completion
Jul 1, 2014
Results posted
Mar 12, 2019
Last update
Mar 12, 2019

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion